ABSTRACT Microbes live as densely populated multicellular surface-attached biofilm communities embedded in self-generated, extracellular polymeric substances (EPSs). EPSs serve as a scaffold for cross-linking biofilm cells and support development of biofilm architecture and functions. Biofilms can have a clear negative impact on humans, where biofilms are a common denominator in many chronic diseases in which they prime development of destructive inflammatory conditions and the failure of our immune system to efficiently cope with them. Our current assortment of antimicrobial agents cannot efficiently eradicate biofilms. For industrial applications, the removal of biofilms within production machinery in the paper and hygienic food packaging industry, cooling water circuits, and drinking water manufacturing systems can be critical for the safety and efficacy of those processes. Biofilm formation is a dynamic process that involves microbial cell migration, cell-to-cell signaling and interactions, EPS synthesis, and cell-EPS interactions. Recent progress of fundamental biofilm research has shed light on novel chemical biology strategies for biofilm control. In this article, chemical biology strategies targeting the bacterial intercellular and intracellular signaling pathways will be discussed.
SIGNALING PATHWAYS REGULATING BACTERIAL BIOFILM FORMATION
Signaling pathways are required for bacterial biofilm formation and antimicrobial resistance. Among them, quorum sensing (QS) and c-di-GMP signaling are the best characterized. QS is a widely distributed intercellular signaling mechanism by which microorganisms regulate gene expression in response to small diffusible signaling molecules (1) . Bacteria have developed oligopeptides, N-acyl homoserine lactones (HSLs), and autoinducer-2 as signal molecules (1) . When the QS signal molecules reach a local threshold concentration, they can interact with specific receptors and impact the expression of hundreds of genes. Many of the QSregulated genes (motility, biosurfacant synthesis, EPS synthesis) are required for the biofilm formation and antibiotic resistance of various bacterial species (2) .
Cyclic di-GMP (c-di-GMP) is a secondary messenger which mediates signal transduction in many Gramnegative species of bacteria (3) . Based on widely distributed sequence similarities and known functionality in a few bacterial species, c-di-GMP is believed to play an essential role in determining the lifestyles of a wide range of bacteria. When the intracellular c-di-GMP content is high, bacteria cells tend to downregulate motility and increase synthesis of extracellular polymeric substances and thus facilitate biofilm formation. In contrast, lowering the intracellular c-di-GMP content enhances bacterial motility and causes biofilm dispersal. The intracellular c-di-GMP content is determined by a number of proteins equipped with diguanylate cyclase (DGC) activity. Such proteins can catalyze the synthesis of c-di-GMP, whereas proteins equipped with phosphodiester-ase (PDE) activities degrade c-di-GMP. Many species contain multiple such proteins with DGC and PDE activities, which presumably offers bacteria a great degree of flexibility in how they can modulate their intracellular c-di-GMP content in response to different environmental stimuli (3) . Recently, small noncoding RNAs (sRNAs) were found to participate in both QS and c-di-GMP signaling transduction and thus modulate biofilm formation posttranscriptionally. sRNAs often interact with regulatory proteins involved in QS and c-di-GMP pathways and can thus serve as potential targets for designing antibiofilm compounds (4).
CHEMICAL BIOLOGY STRATEGIES TARGETING QS
For decades, QS has been recognized as a key target for development of the next generation of antimicrobial agents. Chemical blockage of QS was shown to reduce production of virulence factors, attenuate bacteria in mouse models of infection, and reduce biofilm resistance by various bacterial pathogens (5-7). Efforts directed toward identifying functional QS inhibitors (QSIs) started in the 1990s (8, 9) . Multiple strategies have been developed to interfere with bacterial QS including but not limited to (i) competitive binding of inhibitors to the QS receptors (10), (ii) inhibiting synthesis of QS signals (11), (iii) enzymatic degradation of QS signals (12) , and (iv) posttranscriptional control of QS genes via sRNAs (13) .
Among these strategies, preventing the QS receptors (also referred to as LuxR-type receptors) to perceive their native signals, seems to be the most successfully employed strategy to identify QSIs that would also show functionality in animal models of infection. Chemicals capable of blocking QS have been referred to as antipathogenic or antivirulence drugs (14) . To find functional chemicals, Rasmussen and coworkers developed three QSI selector (QSIS) systems by fusing different report genes to QS-regulated promoters ( Fig. 1) (10) . Natural as well as synthetic compounds have been identified to specifically bind to the LuxR-type receptors (10) . Besides the classic LuxR-type receptors, QSIs targeting other types of receptors for QS signals have also been identified. Pseudomonas aeruginosa has an alkyl-quinolone (AQ)-dependent QS system in addition to its two N-acyl-HSL QS systems to regulate expression of a range of virulence genes (15) . The P. aeruginosa AQ QS system has a LysR-type transcriptional regulator protein, PqsR (also known as MvfR), as the receptor of multiple 2-alkyl-4-quinolones including the Pseudomonas quinolone signal (2-heptyl-3-hydroxy-4[1H]-quinolone) and its precursor 2-heptyl-4-hydroxyquinoline (16) .
Ilangovan and coworkers have obtained the crystal structures of the PqsR co-inducer binding domain and a complex with the native agonist 2-nonyl-4-hydroxyquinoline (17) . Based on the structure analysis of PqsR, they employed a ligand-based design strategy and evaluated a series of 50 AQ and novel quinazolinone analogues for their impact on AQ QS. This study provides novel insights for development of antivirulence drugs by targeting the AQ receptor PqsR (17) .
Some 20 years ago, screening for QSI compounds involved plate-based phenotypic assays, such as observing the change of QS-regulated motility and pigment production in the presence of potential QSIs (8, 18) . The introduction of gfp-based QS reporter fusion vectors has made possible the application of microplatebased high-throughput screening of QSIs (19) . Recent advances in QSI screening strategies include in silico virtual screening, cell-free screening, and in vivo screening (20) . Virtual screening of QSI relied on high-resolution crystal structures of QS receptors. Recently, the crystal structure of the ligand-binding domain of the P. aeru- (C) The QSIS3 system is also based on LuxR regulation. The npt and gfp genes, conferring kanamycin resistance and green fluorescence, respectively, are controlled by the cI repressor, which in turn is regulated by QS through the luxI promoter. The system was established in E. coli. ginosa LasR protein bound to its native signal 3-oxo-C (12)-acyl-HSL lactone was solved and provided clues of atomic interactions between an acyl-HSL receptor and its cognate signal molecule. Molecular docking-based in silico virtual screening was performed based on the LasR crystal structures. Several natural compounds and recognized drugs with distinct structures to the 3-oxo-C (12)-acyl-HSL were identified as specific LasR inhibitors and were able to repress LasR-regulated virulence factors (21, 22) . Because the synthesis of QS signals requires enzymes such as acyl-HSL synthases, a cell-free coupled enzyme assay based on the commercially available S-adenosyl homocysteine assay was developed by Christensen and coworkers (23) to screen inhibitors of acyl-HSL synthases. In this assay, the Burkholderia mallei acyl-HSL synthase, BmaI1, was chosen as the primary target for screening, and the fluorescent compound resorufin production is dependent on acyl-HSL synthesis. By using this screen, they identified and characterized several acyl-HSL synthase inhibitors.
Extracellular inactivation or interference of the function of QS signals is another strategy to reduce bacterial QS-mediated virulence. For example, N-acyl-HSL acylases are found to be produced by both prokaryotic and eukaryotic species and can degrade the N-acyl-HSLs produced by pathogens (12, 24) . In addition to regulating production of virulence factors, the QS signals were reported to act directly as virulence factors. Evidence has shown that a low concentration of the P. aeruginosa 3-oxo-C (12)-acyl-HSL can repress NF-κB transcriptional activity and cause apoptosis (25, 26) . To target the direct virulence effects of 3-oxo-C (12)-acyl-HSL, Valentine and coworkers developed a cell-based high-throughput screen to identify small molecules that restore NF-κB transcriptional activity of a fisher rat thyroid epithelial cell line in the presence of 3-oxo-C (12)-acyl-HSL. This cell line contains a NF-κB-dependent luciferase reporter, and luciferase expression can be efficiently induced after incubation with lipopolysaccharide derived from P. aeruginosa. The presence of 20 μM 3-oxo-C (12)-acyl-HSL lactone greatly repressed the lipopolysaccharide-induced luciferase expression. Screening of 25,600 synthetic, drug-like small molecules has lead to the identification of triazolo [4,3-a] quinolines that can restore NF-κB-induced responses in cell lines (27) . This study shed light on the search for small molecules that could directly interfere with the virulence effects generated by the QS signals.
Several sRNAs have been reported to control QS at different levels. For example, in P. aeruginosa, the GacS/ GacA two-component system activates expression of two sRNAs denoted RsmY and RsmZ, which are required to sequester a QS translational repressor, RsmA (28, 29) . RsmA can prevent ribosome binding of its target mRNAs (including QS-regulated mRNAs) and thus represses their translation. High concentrations of RsmY and RsmZ are required to bind RsmA and abolish its function. Similarly, another sRNA, CrcZ, whose expression is under the control of the CbrA/CbrB twocomponent system (30) , was required to sequester a pqs QS repressor, the catabolite repression control protein Crc (31) . Another two sets of sRNAs, prrF1/prrF2 and PhrS, were shown to negatively and positively regulate expression of the P. aeruginosa pqs QS genes (32, 33) . The abundance of sRNAs encoded by bacterial genomes has thus provided multiple potential targets for designing specific QS inhibitors. Active compounds that are able to interfere with the expression of sRNAs were already found to efficiently inhibit QS and virulence (13) .
Unlike conventional antibiotics, QSIs do not directly inhibit the growth of bacteria and thus are believed to pose less selective pressure for the development-resistant strains (5). However, P. aeruginosa LasR mutants that cannot recognize the 3-oxo-C (12)-acyl-HSL were frequently observed in clinical isolates (34) (35) (36) , which indicates that a functional QS system isn't required during long-term colonization. Mellbye and Schuster designed a proof-of-principle experiment to show that QSI resistance could not spread, because QS cheaters can affect nutrient uptake and delay growth of the entire population (37) . In another study, a placebo-controlled, azithromycin (a recognized antibiotic with QSI properties) pneumonia-prevention trial was performed and showed that the lasR (QS)-mutants appeared less frequently among the population in the presence of QSI than in the absence of QSI and thus QSI selected for cooperation in P. aeruginosa populations during infection (38) . It is therefore likely that QSI drugs may be functional during extended periods of clinical usage. More interestingly, recent work from Lee and coworkers reported that a new QS signal, IQS, can be employed by the P. aeruginosa lasR mutant to coordinate the expression of virulence genes that are normally regulated by the las QS system (39) . The production of IQS can be activated by phosphate limitation in the absence of LasR. This study highlights the complexity of QS systems and suggests potential novel targets for designing QSIs.
CHEMICAL BIOLOGY STRATEGIES TARGETING C-DI-GMP
It has been a while since researchers realized that bacterial c-di-GMP signaling could be a promising target for ASMscience.org/MicrobiolSpectrumdevelopment of chemical biology-based biofilm control. Compounds targeting c-di-GMP can be used to prevent biofilm formation or disperse late-stage biofilms. Bacterial genomes often encode multiple copies of DGCs and PDEs, presumably to modulate c-di-GMP levels in response to diverse environmental cues. Understanding the working mechanisms of DGCs and PDEs can lead to identification of chemical compounds that inhibit DGCs or activate PDEs. C-di-GMP signal transduction requires PilZ domain proteins or riboswitches that can directly bind to c-di-GMP (3, 40) . These c-di-GMP receptors can also be targets for designing compounds targeting c-di-GMP signaling.
Several fluorescence-based biosensors have been developed to monitor intracellular c-di-GMP levels. Binding of c-di-GMP to a receptor protein can often change its conformation. Based on this, several groups designed fluorescence resonance energy transfer (FRET)-based reporter vectors to monitor c-di-GMP levels within single bacterial cells. Christen and coworkers constructed a set of genetically encoded FRET-based biosensors by fusing PilZ proteins between cyan fluorescent proteins (CFPs) and yellow fluorescent proteins (YFPs) (41) . They used the FRET/CFP emission ratio to reflect cellular c-di-GMP levels and found that there is an asymmetrical distribution of c-di-GMP in the progeny that correlates with the time of cell division and polarization for motile bacteria. The intracellular c-di-GMP levels were shown to be significantly lower in the flagellated cell than in the nonflagellated cells of P. aeruginosa (41) . In another study, Ho and coworkers constructed two FRET-based c-di-GMP biosensors, cdg-S1 and cdg-S2, by fusing CFPs and YFPs to two PilZ proteins, MrkH and VCA0042, respectively (Fig. 2) (42) . These two biosensors exhibit similar response dynamics intracellularly but with different dynamic ranges, so they can be used to test effects of different compounds to c-di-GMP, perturbation (Fig. 2) (42) . Using these two biosensors, the authors evaluated the time-dependent changes in the FRET efficiencies of biosensor strains after exposure to compounds which can enhance or decrease c-di-GMP, and showed that Escherichia coli cells reduce intracellular c-di-GMP content shortly after being engulfed by macrophages (42). Rybtke and coworkers created a c-di-GMP reporter strain by transcriptionally fusing the c-di-GMP-responsive P. aeruginosa cdrA promoter to gfp (43) . CdrA is an adhesive matrix protein that can bind the P. aeruginosa Psl exopolysaccharide and cause aggregation (44) . The p cdrA -gfp reporter construct can be transformed into different P. aeruginosa strains and reflects the intracellular c-di-GMP level in real time.
A range of synthetic and natural compounds have been discovered that can affect c-di-GMP signaling or competitively bind to DGCs via different approaches. Several groups synthesized analogs of c-di-GMPs and proved that these analogs could efficiently inhibit the enzymatic activity of DGCs (45, 46) . High-throughput screens have also been employed to identify c-di-GMPinhibiting compounds. Sambanthamoorthy and coworkers constructed a Vibrio cholerae c-di-GMP reporter strain to perform cell-based high-throughput screening of c-di-GMP interference compounds (47) . Initially, they engineered a V. cholerae strain to constitutively express the DGC VC1216. Then they introduced a c-di-GMP reporter plasmid (which carries a transcriptionally fused c-di-GMP-inducible promoter of the VC1673 gene to the luciferase operon [P VC1673 -lux]) into the high c-di-GMP-level V. cholerae VC1216 background. The high intracellular c-di-GMP of this strain promotes the expression of P VC1673 -lux fusion with luciferase activity as an indicator of intracellular c-di-GMP levels. The researchers cultivated the V. cholerae (VC1216)/P VC1673 -lux strain in the presence of 66,000 compounds/natural-product extracts and identified compounds and natural-product extracts that reduced P VC1673 -lux fusion expression without negatively impacting V. cholerae growth. During this screening, they identified 358 compounds that exhibited greater than 50% inhibition of P VC1673 -lux fusion expression, and 184 identified compounds had IC 50 of less than 10 μM (47).
In another study, Sambanthamoorthy and coworkers used an in silico pharmacophore-based screen to identify small-molecule inhibitors of DGCs (48) . Twodimensional pharmacophores were generated based on the PleD DGC of Caulobacter crescentus, and a focused library from the commercially available compound database was generated using queries derived from the two-dimensional phamacophores. In silico screening of this focused library was performed against the c-di-GMP binding site of the published crystal structure of PleD DGC (Pubmed: 15569936) by using Molecular Operating Environment (Chemical Computing Group, Quebec, Canada). The top-ranking compounds were then purchased and tested for their ability to inhibit DGC activity in vitro. Four small molecules were discovered in this screening to antagonize DGC activities and inhibit biofilm formation by P. aeruginosa and Acinetobacter baumannii (48) .
Several natural compounds and recognized drugs were found to inhibit c-di-GMP signaling of bacteria. Ohana and coworkers reported that the glycosylated triterpenoid saponin is a specific inhibitor of DGC from Acetobacter xylinum (49) . An immunosuppressive drug, azathioprine, was found by Antoniani and coworkers to inhibit c-di-GMP synthesis via perturbation of bacterial intracellular nucleotide pools (50) . Recently, nitric oxide (NO)-generating compounds were reported to be promising agents to control biofilms via c-di-GMP signaling interference (51, 52) . Barraud and coworkers synthesized a chemically stable cephalosporin-3′-diazeniumdiolate NO-donor prodrug that can be activated by bacterial β-lactamases after exposure to biofilms and cause biofilm dispersal (53) .
Similar to the case for QSI compounds, there is a profound lack of animal models to test identified c-di-GMP-signaling interference compounds. Christensen and coworkers carried out a proof-of-concept study to show that biofilm dispersal can be induced via reducing intracellular c-di-GMP content in a P. aeruginosa foreign-body mouse infection model (54) . In this work, reduction of c-di-GMP in P. aeruginosa cells was achieved via a genetic approach to avoid pleotropic effects of chemical-based approaches. An E. coli PDE, YhjH, was fused to an arabinose-inducible p BAD promoter and transformed into the P. aeruginosa wild-type PAO1 strain. Biofilms were formed by the PAO1/p BAD -yhjH strain on the surface of silicone implants located in the peritoneal cavity of mice. In vivo dispersal of biofilms was observed after induction of the YhjH protein via arabinose (54) . This study provides the first real-time observation of biofilm dispersal and can serve as a model system to test the impact of c-di-GMP interference compounds in the future.
SUMMARY
Bacterial biofilms are notorious in many industrial and hospital settings and cause a huge economic burden to our society. The fundamental biofilm mechanism studies in recent years have opened novel routes for development of biofilm-controlling approaches. Chemical biology approaches to combat biofilms are being widely investigated by researchers, including QS inhibitors, c-di-GMP-signaling interference compounds, anti-attachment compounds, and so on. A few of these compounds have been shown to be functional in vivo and to be promising antibiofilm agents for further development. These studies will further provide molecular targets and biomarkers for development of antibiofilm agents.
